Through our GPM methodology of network meta-analysis, we hope to have a more robust outline of the most uptodate ranking of individual members of the SGLT2 inhibitor class regarding their efficacy in patients with type II diabetes. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.